September 19, 2020Open Access
Ver artículo completoOsimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
In patients with stage IB to IIIA EGFR mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).